Oral Ivermectin for Chikungunya Viral Infection

Prince of Songkla University120 enrolled

Overview

Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

120

Conditions

Clinical Syndrome

Interventions

IvermectinDRUG

3-day 1 daily dose of 400 μg/kg oral ivermectin

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit Exclusion Criteria: * patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit

Locations (1)

Prince of Songkla University

Hat Yai, Changwat Songkhla, Thailand

Outcomes

Primary Outcomes

Day of fever clearance

120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days

Time frame: 1 week

Secondary Outcomes

Day of virologic clearance

120 participants would be obtained blood examination for virological testing every day until virological clearance at least in 7 days

Time frame: 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.